one
concern
tradit
smallpox
vaccin
inadvert
spread
viru
atop
immunocompromis
contact
reduc
risk
test
abil
povidon
iodin
inactiv
infecti
viru
vaccin
site
begin
day
transcutan
smallpox
vaccin
ointment
rapidli
inactiv
viru
skin
without
reduc
neutral
antibodi
titer
antivir
cell
respons
moreov
delay
healingeschar
separ
follow
povidon
iodin
applic
togeth
indic
administr
antivir
antimicrobi
cream
effect
block
viru
shed
tradit
smallpox
vaccin
reduc
risk
autoinocul
contact
spread
although
extinct
natur
smallpox
remain
public
health
concern
due
remot
possibl
could
use
biolog
weapon
addit
close
relat
orthopoxviru
monkeypox
continu
caus
substanti
number
outbreak
democrat
republ
congo
recent
studi
document
monkeypox
outbreak
neighbor
african
countri
sudan
first
import
monkeypox
outbreak
record
western
hemispher
occur
unit
state
result
case
monkeypox
rang
asymptomat
infect
proport
previous
vaccin
individu
lifethreaten
infect
small
percentag
unvaccin
monkeypox
patient
smallpox
vaccin
accomplish
cutan
infect
live
vaccinia
viru
orthopoxviru
provid
protect
immun
member
orthopoxviru
genu
includ
smallpox
monkeypox
cowpox
gener
flulik
symptom
common
advers
event
observ
follow
smallpox
vaccin
rare
complic
gener
vaccinia
autoinocul
ocular
infect
known
occur
smallpox
vaccin
also
fatal
estim
death
occur
everi
one
million
vaccin
administ
modern
era
univers
smallpox
vaccin
end
erad
natur
occur
smallpox
sever
complic
occur
person
directli
vaccin
eg
vaccinia
necrosum
sever
sometim
lethal
infect
may
occur
due
contact
spread
recent
vaccin
individu
atop
contact
result
eczema
vaccinatum
ev
follow
mass
vaccin
million
peopl
england
wale
case
ev
report
evassoci
death
case
mortal
rate
ev
patient
full
clinic
detail
obtain
realiz
least
case
due
contact
spread
close
contact
recent
receiv
smallpox
vaccin
likewis
follow
vaccin
approxim
million
peopl
new
york
case
gener
vaccinia
ev
case
occur
due
contact
spread
extens
epidemiolog
analysi
smallpoxvaccin
associ
death
examin
span
time
determin
death
attribut
primari
smallpox
vaccin
us
due
ev
evassoci
death
us
occur
unvaccin
children
contract
infect
contact
spread
recent
vaccin
individu
recent
indiana
boy
contract
sever
case
ev
father
vaccin
soldier
child
rash
progress
umbil
lesion
cover
keratin
skin
despit
sedat
intub
mechan
ventil
treatment
vaccinia
immun
globulin
vig
child
underw
hyperthermia
hemodynam
instabl
requir
vasopressor
support
child
surviv
lifethreaten
infect
follow
hospit
day
treatment
cidofovir
experiment
drug
addit
vig
viru
shed
effect
reduc
follow
smallpox
vaccin
spread
suscept
contact
ensu
event
may
prevent
studi
determin
one
could
effici
reduc
risk
viru
shed
contact
spread
inocul
site
follow
smallpox
vaccin
appli
antivir
cream
povidon
iodin
ointment
earli
day
vaccin
also
determin
whether
simpl
safeti
precaut
would
interfer
develop
antivir
antibodi
cell
respons
delay
time
requir
eschar
separ
believ
approach
describ
use
prevent
autoinocul
inadvert
ocular
infect
viru
transmiss
vulner
contact
togeth
reduc
least
one
paramet
morbid
mortal
associ
tradit
smallpox
vaccin
subject
screen
contraind
smallpox
vaccin
provid
inform
written
consent
sign
research
author
form
compli
us
health
insur
portabl
act
fill
medic
histori
questionnair
inocul
perform
use
bifurc
needl
hold
drop
vaccin
dryvax
press
time
skin
upper
arm
vaccin
site
cover
semiperm
adhes
membran
gauz
day
postvaccin
subject
either
continu
use
occlus
dress
gauz
plu
tape
observ
studi
subject
vaccin
due
occup
risk
group
base
occup
health
care
worker
vaccin
part
oregon
bioterror
prepared
effort
repres
control
group
employe
oregon
health
scienc
univers
ohsu
oregon
nation
primat
research
center
onprc
repres
povidon
iodin
ointment
pio
group
vaccin
due
work
relat
orthopoxviru
research
sampl
obtain
comparison
primari
vaccine
ohsuonprc
employe
piotreat
group
subject
undilut
povidon
iodin
ointment
povidoneiodin
avail
iodin
profession
dispos
inc
appli
directli
vaccin
site
reappli
bandag
chang
day
apart
day
postvaccin
day
eschar
slough
pio
administ
prior
day
postvaccin
order
allow
vaccin
site
form
success
jennerian
pustul
formal
standard
use
determin
vaccin
efficaci
subject
given
instruct
pio
administr
vaccin
diari
keep
daili
record
reaction
vaccin
complianc
studi
protocol
monitor
studi
visit
blood
sampl
ml
collect
prior
vaccin
week
vaccin
peripher
blood
mononuclear
cell
pbmc
cryopreserv
aliquot
store
liquid
nitrogen
plasma
serum
sampl
store
viru
shed
analysi
n
primari
vaccine
revaccin
subject
control
pio
administr
pio
group
n
primari
vaccine
revaccin
subject
immunolog
analysi
n
control
subject
pio
subject
repres
revaccin
eschar
separ
analysi
n
control
subject
pio
subject
repres
revaccin
institut
review
board
oregon
health
scienc
univers
approv
clinic
studi
determin
antivir
effect
pio
vitro
use
vaccinia
strain
wr
infect
cell
lysat
prepar
round
freezethaw
cycl
follow
sonic
centrifug
remov
cellular
debri
twenti
aliquot
viru
ad
pio
dilut
heatinactiv
human
plasma
minut
sampl
incub
indic
period
time
prior
addit
ml
medium
immedi
prior
plate
onto
multipl
well
plaqu
assay
plate
describ
comparison
solut
thermacin
chlorhexidin
test
antivir
activ
vaccinia
plaqu
assay
techniqu
level
infecti
viru
vaccin
site
determin
swab
skin
time
vertic
time
horizont
steril
cotton
swab
prewet
steril
water
swab
rins
ml
pb
contain
fb
plaqu
assay
perform
day
swab
occur
plaqu
assay
carri
incub
serial
tenfold
dilut
sampl
vero
cell
confluent
plate
well
overlaid
ml
agaros
emem
contain
fb
incub
day
allow
plaqu
format
residu
pio
dilut
final
volum
agar
overlay
perform
dilut
pio
low
level
antivir
activ
longer
observ
see
figur
monolay
fix
acet
acid
agaros
remov
plaqu
visual
stain
crystal
violet
pb
contain
formaldehyd
intracellular
cytokin
stain
perform
previous
describ
briefli
pbmc
cultur
roundbottom
plate
co
rpmi
contain
mm
hepe
lglutamin
antibiot
heat
inactiv
fb
hyclon
without
vaccinia
viru
sucros
gradientpurifi
intracellular
matur
viru
imv
vaccinia
strain
western
reserv
optim
moi
h
cultur
brefeldin
icn
ad
care
without
disturb
cell
final
concentr
addit
h
cell
stain
overnight
antibodi
specif
clone
beckman
coulter
clone
pharmingen
cell
fix
permeabil
stain
intracellularli
use
antibodi
clone
clone
pharmingen
sampl
acquir
fac
calibur
beckton
dickinson
use
cellquest
softwar
beckton
dickinson
acquir
million
event
per
sampl
data
analyz
use
cellquest
softwar
live
cell
gate
perform
base
forward
side
scatter
characterist
number
cell
quantit
first
gate
live
cell
subtract
number
event
uninfect
cultur
assay
contain
pbmc
posit
control
subject
year
postsmallpox
vaccin
score
sd
cell
per
cell
sd
cell
per
cell
respect
one
neg
control
sampl
consist
pbmc
subject
includ
assay
qualiti
control
purpos
cell
per
cell
sd
cell
per
cell
respect
vacciniaspecif
elisa
assay
perform
previous
describ
use
vaccinia
whole
viru
lysat
inactiv
pretreat
h
hour
intern
posit
control
standard
includ
plate
normal
elisa
valu
plate
assay
perform
differ
day
antibodi
titer
determin
loglog
transform
linear
portion
curv
optic
densiti
od
unit
use
endpoint
convers
perform
final
valu
neutral
assay
perform
prepar
serial
dilut
heatinactiv
serum
incub
vaccinia
pfu
h
prior
plate
mixtur
vero
cell
monolay
measur
plaqu
form
viru
describ
nt
defin
serum
dilut
requir
reduct
plaqu
use
logarithm
transform
linear
portion
curv
calcul
titer
convers
perform
final
valu
outcom
measur
log
base
transform
prior
analysi
adjust
outlier
skew
nonnorm
distribut
popul
characterist
compar
treat
untreat
subject
use
twosampl
ttest
continu
measur
fisher
exact
test
categor
measur
follow
smallpox
vaccin
exact
binomi
calcul
use
assess
whether
subject
respond
pio
loss
detect
infecti
viru
skin
would
expect
random
condit
sinc
probabl
respons
random
condit
unknown
suspect
small
conserv
compar
whether
probabl
respons
differ
averag
baselin
antibodi
tcell
nt
count
ratio
baselin
count
pio
treat
control
subject
first
compar
use
twosampl
ttest
ancova
model
fit
adjust
subject
characterist
year
post
previou
vaccin
current
age
gender
presenc
allergi
asthma
ratio
outcom
addit
adjust
baselin
antibodi
nt
level
respect
time
eschar
separ
curv
two
group
estim
use
kaplanmei
analysi
equival
surviv
curv
test
use
logrank
test
pvalu
less
consid
signific
varieti
disinfect
use
inactiv
orthopoxvirus
laboratori
set
mani
unsuit
topic
use
due
toxic
andor
inher
health
risk
contrast
pio
effect
iodinebas
broadspectrum
antimicrobi
cream
use
extens
topic
antisept
first
experi
measur
specif
antivir
activ
infecti
vaccinia
viru
vitro
fig
use
high
concentr
vaccinia
pfuml
viru
titer
skin
lesion
monkeypox
patient
smallpox
patient
smallpox
vaccine
rare
reach
high
level
presum
could
inactiv
high
titer
viru
lower
titer
would
also
effici
inactiv
protein
contamin
interfer
mani
type
antisept
orthopoxviru
lesion
may
releas
substanti
volum
virusinfect
proteinaci
exud
reach
pustular
stage
develop
reason
test
direct
antivir
activ
pio
alon
dilut
human
plasma
mimic
exud
releas
orthopoxviru
lesion
viru
titer
measur
plaqu
assay
exposur
differ
concentr
pio
fig
within
hour
achiev
greater
one
millionfold
reduct
viru
titer
vaccinia
incub
plasma
contain
littl
volum
volum
concentr
pio
higher
concentr
vaccinia
titer
drop
limit
detect
pfuml
concentr
pio
infecti
viru
detect
experi
pfuml
compar
pfuml
untreat
control
lower
concentr
pio
longer
effect
reduc
viru
titer
vitro
unlik
amount
dilut
would
occur
skin
surfac
term
clinic
relev
topic
agent
solut
contain
chlorhexidin
thermacin
reduc
vaccinia
titer
human
plasma
pfuml
pfuml
pfuml
respect
data
shown
indic
reduct
viru
titer
larg
ineffici
compar
reduct
viru
level
obtain
similar
concentr
pio
speed
viru
titer
could
deplet
also
determin
fig
experi
observ
greater
one
millionfold
reduct
infecti
viru
littl
minut
use
vacciniaspik
plasma
contain
pio
indic
inactiv
infecti
viru
rapid
vitro
condit
mimic
proteinrich
exud
observ
pustular
lesion
orthopoxvirusinfect
skin
determin
pio
work
best
inactiv
infecti
orthopoxviru
vitro
test
antivir
effect
topic
antisept
cohort
subject
undergo
tradit
smallpox
vaccin
revaccin
smallpox
perform
subject
receiv
prior
smallpox
vaccin
greater
year
ago
tabl
common
advers
event
record
itch
vaccin
site
swollentend
lymph
node
seriou
advers
event
report
prevent
earli
viru
shed
subject
wore
semiperm
tegaderm
dress
chang
everi
day
day
postvaccin
vaccin
take
record
vaccin
site
swab
replicationcompet
viru
level
infecti
viru
typic
lower
follow
revaccin
compar
primari
vaccin
although
subject
receiv
pio
demonstr
infecti
viru
one
time
point
day
data
shown
titer
rang
detect
n
high
pfuml
time
pio
administr
day
postvaccin
mean
titer
pfuml
similar
previou
studi
also
note
peak
approxim
pfu
day
revaccin
pio
appli
directli
site
follow
appli
fresh
tegaderm
patch
vaccin
site
swab
infecti
viru
within
hour
initi
applic
administr
pio
vaccin
site
infecti
viru
drop
limit
detect
pfuml
subject
one
subject
pretreat
titer
pfuml
residu
viru
remain
titer
pfuml
reduct
titer
howev
review
clinic
note
realiz
subject
eschar
slough
second
swab
procedur
like
residu
infecti
viru
sequest
eschar
direct
contact
pio
subject
undergo
primari
smallpox
vaccin
exhibit
higher
viru
shed
day
postinfect
mean
pfuml
n
pio
treatment
elimin
infecti
viru
level
detect
subject
data
shown
loss
infecti
viru
observ
second
swab
vaccin
site
could
due
least
part
remov
infecti
viru
first
swab
procedur
determin
play
role
outcom
experi
swab
vaccin
site
anoth
group
primari
vaccine
appli
pio
mean
vaccinia
titer
day
postvaccin
drop
slightli
pfuml
follow
first
swab
pfuml
follow
second
swab
procedur
perform
hour
later
indic
physic
remov
infecti
viru
play
minor
role
loss
infecti
viru
observ
follow
administr
pio
directli
site
vaccin
number
studi
examin
frequenc
detect
infecti
viru
outsid
differ
bandag
use
cover
inocul
site
follow
smallpox
vaccin
rigor
approach
measur
infecti
viru
insid
tegaderm
patchesbandag
use
cover
vaccin
site
subject
treat
pio
gauz
pad
test
pio
administr
began
day
postvaccin
bandag
contain
detect
level
infecti
viru
limit
detect
pfuml
even
though
direct
contact
vaccin
site
absorb
exudatepio
pustular
lesion
period
highest
likelihood
viru
shed
also
test
gauz
pad
primari
vaccine
use
pio
found
bandag
contain
detect
viru
examin
day
vaccin
contrast
detect
infecti
viru
insid
gauz
pad
obtain
day
vaccin
primari
vaccine
appli
pio
rang
pfuml
pfuml
togeth
indic
pio
abl
effect
inactiv
infecti
viru
skin
surfac
well
insid
protect
bandag
like
significantli
reduc
inadvert
viru
shed
andor
spread
suscept
contact
concern
inactiv
infecti
viru
site
inocul
might
result
decreas
antigen
load
reduc
antivir
immun
follow
smallpox
vaccin
examin
issu
drew
blood
sampl
prior
revaccin
week
postvaccin
measur
virusspecif
cell
respons
intracellular
cytokin
stain
icc
analysi
previous
describ
fig
follow
hour
direct
ex
vivo
stimul
optim
concentr
purifi
vaccinia
virusspecif
cell
respons
measur
stain
cell
number
virusspecif
cell
determin
quantit
number
cell
cultur
stimul
vaccinia
subtract
nonspecif
cytokineposit
event
cultur
incub
medium
alon
subject
control
group
ie
pio
pio
group
receiv
smallpox
vaccin
distant
past
major
retain
preexist
cell
memori
could
detect
prior
revaccin
fig
found
signific
differ
cell
memori
group
prior
vaccin
p
group
demonstr
sharp
rise
virusspecif
cell
number
within
week
revaccin
signific
differ
group
p
contrast
cell
memori
approxim
half
individu
receiv
smallpox
vaccin
distant
past
antivir
cell
respons
limit
detect
cell
within
year
postvaccin
similar
previou
result
proport
subject
group
n
control
n
pio
subject
p
lost
detect
cell
memori
follow
smallpox
vaccin
year
previous
follow
revaccin
control
group
subject
pio
treat
subject
elicit
demonstr
boost
vacciniaspecif
cell
memori
signific
differ
overal
level
cell
memori
follow
revaccin
p
togeth
indic
topic
applic
pio
alter
induct
vacciniaspecif
cell
respons
follow
revaccin
smallpox
play
import
role
protect
class
virus
shown
necessari
suffici
protect
nonhuman
primat
lethal
monkeypox
infect
model
similar
human
smallpox
infect
determin
pio
administr
would
alter
humor
immun
follow
smallpox
vaccin
examin
antivir
antibodi
respons
two
independ
approach
vacciniaspecif
elisa
assay
measur
total
virusspecif
antibodi
respons
fig
vacciniaspecif
neutral
assay
measur
biolog
relev
antibodi
respons
fig
control
group
margin
higher
preexist
elisa
titer
prior
vaccin
statist
signific
p
follow
revaccin
increas
approxim
differ
geometr
mean
titer
group
fig
although
modestli
signific
p
longer
statist
signific
adjust
baselin
titer
demograph
characterist
two
group
p
data
shown
anoth
benchmark
evalu
success
smallpox
vaccin
develop
higher
increas
antibodi
level
regard
control
piotreat
subject
exhibit
greater
increas
antibodi
level
elisa
signific
differ
group
p
fisher
exact
test
case
virusspecif
neutral
antibodi
titer
signific
differ
group
either
p
p
revaccin
fig
adjust
baselin
titer
group
characterist
data
shown
one
studi
indic
vacciniaspecif
neutral
titer
higher
could
consid
fulli
protect
smallpox
base
assumpt
control
piotreat
subject
achiev
success
smallpox
vaccin
togeth
indic
biolog
relev
antibodi
respons
inhibit
administr
pio
individu
undergo
tradit
smallpox
vaccin
gener
consid
infecti
detach
eschar
vaccin
site
routin
practic
vaccin
site
kept
dri
order
aid
wound
heal
eschar
separ
two
potenti
caveat
approach
repeat
applic
pio
could
result
delay
heal
eschar
separ
could
lead
contact
dermat
studi
evid
contact
dermat
poitreat
site
vaccin
site
poi
group
display
typic
morpholog
progress
papul
vesicl
pustul
eschar
seen
untreat
site
fig
median
time
eschar
separ
piotreat
subject
day
ci
day
ci
control
subject
median
time
eschar
separ
differ
statist
two
group
fig
p
logrank
test
time
eschar
separ
similar
result
previou
studi
indic
prolong
topic
administr
pio
abl
inactiv
infecti
viru
vaccin
site
without
delay
wound
heal
time
eschar
separ
studi
test
efficaci
topic
pio
administr
mean
reduc
viru
shed
skin
follow
tradit
smallpox
vaccin
topic
agent
highli
effect
reduc
elimin
infecti
viru
skin
surfac
bandag
use
cover
vaccin
site
although
begin
pio
applic
day
postvaccin
futur
studi
import
determin
topic
applic
could
occur
earlier
time
point
day
inocul
importantli
studi
show
pio
administr
interfer
develop
cellular
humor
immun
respons
imped
heal
process
eschar
separ
follow
smallpox
vaccin
despit
proper
instruct
care
vaccin
site
contact
spread
vaccinia
viru
ocular
infect
continu
problem
among
vaccin
militari
personnel
led
secondari
even
tertiari
transfer
viru
rare
instanc
one
unfortun
exampl
describ
case
inadvert
household
spread
recent
vaccin
us
soldier
result
infect
breastfeed
wife
spread
viru
infant
daughter
develop
vacciniacultur
posit
vesicl
labial
philtrum
well
lesion
cheek
tongu
prevent
autoinocul
ocular
infect
goggl
place
infant
held
soft
restraint
awak
mother
arm
experi
like
could
prevent
viru
shed
reduc
elimin
health
care
worker
use
semiperm
dress
reduc
transmiss
may
financi
feasibl
mass
vaccin
program
initi
us
militari
povidon
iodin
ointment
use
semiperm
dress
simpl
gauz
tape
effect
afford
reduc
inadvert
spread
vaccinia
close
contact
use
antivir
cream
may
import
pustular
stage
infect
dress
sometim
becom
inund
volum
exud
leak
infecti
viru
adhes
protect
cover
interestingli
semiperm
dress
reduc
necessarili
elimin
infecti
viru
transmiss
recoveri
vaccinia
surfac
semiperm
dress
variabl
sampl
test
posit
vaccinia
outer
surfac
direct
comparison
gauz
semiperm
dress
given
diverg
result
occlus
dress
either
effect
equival
gauz
term
reduc
viru
shed
studi
measur
infecti
viru
inner
surfac
dress
found
pio
administr
result
complet
inactiv
vaccinia
infecti
viru
inactiv
protect
dress
even
unlik
viru
shed
could
occur
would
recommend
pio
administr
combin
protect
dress
minim
potenti
inadvert
contact
spread
follow
smallpox
vaccin
anoth
potenti
use
topic
antivir
may
also
form
primari
prophylaxi
administ
ointment
expos
skin
medic
personnel
predispos
individu
atop
dermat
inadvert
come
contact
recent
vaccin
individu
although
wash
soap
water
typic
recommend
deterg
data
shown
commerci
soap
perform
poorli
inactiv
vaccinia
viru
pio
administr
gener
well
toler
applic
antimicrobi
ointment
may
use
treat
orthopoxviru
infect
besid
vaccinia
smallpox
releas
bioterror
event
pio
could
administ
directli
onto
skin
lesion
patient
order
reduc
risk
fomit
spread
hospit
clinic
andor
transport
design
quarantin
site
may
also
use
approach
treat
monkeypox
patient
outbreak
continu
occur
democrat
republ
congo
possibl
neighbor
countri
set
pio
repres
afford
method
reduc
viru
transmiss
time
help
prevent
secondari
bacteri
infect
pustular
stage
diseas
povidoneiodin
ointment
appear
block
viru
replic
skin
eschar
instead
inactiv
viru
releas
skin
surfac
come
direct
contact
assumpt
base
mainli
one
subject
fail
appli
pio
day
postvaccin
instead
remov
protect
bandag
wash
away
residu
pio
soap
water
swab
vaccin
site
within
hour
realiz
oversight
recov
infecti
viru
pfuml
even
though
neg
infecti
viru
pfuml
administr
pio
day
earlier
day
postvaccin
suggest
long
pio
appli
dress
chang
infecti
viru
releas
skin
surfac
rapidli
inactiv
howev
viru
direct
contact
topic
cream
continu
replic
host
immun
system
abl
clear
infect
eschar
separ
like
explain
inactiv
surfac
vaccinia
viru
signific
effect
activ
cellular
humor
immun
respons
figur
remark
edward
jenner
colleagu
first
describ
viru
inactiv
inocul
site
follow
smallpox
vaccin
second
paper
smallpox
vaccin
dr
jenner
realiz
take
robust
caus
substanti
alarm
due
extens
inflamm
one
case
mh
year
age
wrote
pustul
begin
show
disposit
spread
dress
ointment
compos
hydrarg
nitrub
ung
cera
effloresc
cover
plaster
unghydr
fort
topic
applic
continu
daili
day
girl
tenth
day
observ
becam
littl
ill
show
least
symptom
indisposit
afterward
expos
action
variol
matter
complet
resist
word
test
whether
inactiv
surfac
viru
result
loss
protect
antivir
immun
directli
inocul
patient
smallpox
look
resist
infect
smallpox
inocul
ie
variol
standard
care
prior
develop
smallpox
vaccin
jenner
perform
sever
similar
trial
note
viru
could
inactiv
shortli
vaccin
viru
arm
destroy
soon
produc
percept
sicken
yet
children
fulli
protect
cutan
challeng
smallpox
appear
progress
infect
arm
everi
respect
similar
gener
observ
variol
matter
insert
skin
person
previous
undergon
either
cowpox
smallpox
detail
exampl
provid
jenner
third
paper
smallpox
vaccin
addit
publish
letter
receiv
physician
also
inactiv
viru
inocul
site
within
day
vaccin
use
vinegar
water
vitriol
acid
joseph
h
marshal
letter
edward
jenner
appli
ointment
inflam
part
repeat
daili
inflamm
went
mj
tieni
letter
edward
jenner
base
histor
find
studi
use
povidon
iodin
ointment
inactiv
vaccinia
infect
skin
vaccin
site
actual
simpl
modern
extens
studi
perform
year
ago
surpris
find
larg
forgotten
still
provid
evid
inactiv
surfac
viru
interfer
protect
immun
afford
smallpox
vaccin
even
case
wherein
subject
directli
challeng
smallpox
vaccinia
pfu
dilut
heatinactiv
human
plasma
mix
vari
concentr
povidoneiodin
ointment
pio
minut
prior
determin
infecti
viru
level
plaqu
assay
shorter
incub
time
test
use
pio
effect
inactiv
vaccinia
within
minut
effici
inactiv
viru
directli
vaccin
site
test
take
swab
treatment
group
day
hour
applic
pio
subject
preexist
viru
titer
detect
viru
pio
administr
result
signific
declin
potenti
shed
infecti
viru
p
binomi
calcul
sampl
swab
procedur
unroof
eschar
expos
infecti
viru
may
contact
pio
dash
line
indic
limit
detect
sampl
test
prior
vaccin
day
day
rang
day
tradit
smallpox
revaccin
number
vacciniaspecif
cell
measur
number
per
cell
per
cell
open
symbol
repres
score
background
level
observ
incub
medium
alon
vacciniaspecif
antibodi
titer
determin
elisa
measur
total
virusspecif
igg
elisa
unit
neutral
antibodi
assay
measur
abil
antivir
serum
antibodi
neutral
infecti
viru
particl
pio
geometr
mean
limit
detect
tabl
contain
summari
statist
revaccin
subject
divid
treatment
group
medic
inform
avail
subject
pio
treatment
group
significantli
younger
therefor
time
previou
vaccin
shorter
p
respect
two
popul
similar
number
previou
smallpox
vaccin
p
differ
significantli
race
p
pio
treat
group
balanc
male
femal
untreat
group
predomin
femal
p
total
popul
nonsmok
report
allergi
asthma
paramet
differ
two
treatment
group
p
vaccin
author
manuscript
avail
pmc
januari
